港A骨科耗材股集體拉昇 人工關節國家集採擬中選結果出爐利空落地
格隆匯9月14日丨人工關節國家集採擬中選結果出爐,產品降價80%,二級市場解讀為利空出盡是利好,港A骨科耗材股集體拉昇。港股愛康醫療漲近28%,微創醫療漲超10%,威高股份漲8%,春立醫療漲超4%;A股威高骨科漲20%漲停,三友醫療漲17%,佰仁醫療漲超12%,凱利泰漲超15%,大博醫療漲10%漲停,心脈醫療漲近8%。國家組織人工關節集中帶量採購今日在天津開標,擬中選結果在中午出爐。據國家組織高值醫用耗材聯合採購辦公室集中採購組組長高雪介紹,此次擬中選的人工關節產品價格從平均3萬元降到1萬塊以內,降幅達到80%以上。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.